Nöropatik ağrı tedavisinde non-opioid ve opioid ajan kullanımı

Nöropatik ağrı tedavisi yeni tedavilere rağmen hala zordur ve tüm sorunlar ve altta yatan mekanizmaları için işe yarayan tek bir tedavi bulunmamaktadır. Etkin nöropatik ağrı tedavileri için giderek artan kanıtlar göz önüne alınacak olursa, klinisyenin ağrıyı rahatlatmada hangi ilaçların en etkili olduğunu ve ilaçlarla ilişkili en az sayıdaki advers etkileri bilmesi önem kazanmaktadır ve nöropatik ağrı durumlarının tedavi edilmesi için kanıta dayalı bir algoritmaya ihtiyaç duyulmaktadır. İdealde, böyle bir algoritmada non-opioid ve opioid ilaç seçimleri için gereken kanıtlar bir ilacın hem etkinlik hem de yan etkiler açısından diğerleriyle doğrudan bir şekilde karşılaştırılmasına dayalı olmalıdır. Bugün için mevcut olan bu tür doğrudan karşılaştırmalar az sayıdadır.

Anahtar Kelimeler:

Nevralji, Analjezikler, opioid, Anti-enflamatuvar ajanlar, steroid olmayan, Asetaminofen

Treatment of neuropathic pain is difficult despite new treatments and there is no single treatment that Works for all conditions and their underlying mechanisms. Given the increasing evidence for effective treatments of neuropathic pain, it is important for the clinician to know which drugs are most effective neuropathic pain relieving pain and associated with the fewest adverse effects and there is a need for an evidence-based algorithm to treat neuropathic pain conditions. Ideally, the evidence for the non-opioids and opioids choices in such an algorithm would be based on direct comparisons of one drug with another, for both efficacy and side effects. There are very few such direct comparisons available.

Keywords:

Neuralgia, Analgesics, Opioid, Anti-Inflammatory Agents, Non-Steroidal, Acetaminophen,

PDF

___

Attal N, Cruccu G, Haanpaa M, Hansson P, Jensen TS, Nurmikko T, Sampaio C, Sindrup S, Wiffen P. EFSN guidelines on pharmagological treatment of neuropat- hic pain Eur J Neurol 2006; 13: 153-69.
Attal N: Chronic neuropathic pain: mechanisms and treatment. The Clinical journal of pain 2000; 16: 118-130.
Baba H, Kohno T, Moore KA, Woolf CJ: Direct activation of rat spinal dorsal horn neurons by prostaglandin E2. J Neurosci 2001; 21: 1750–1756.
Backonja MM, Serra J: Pharmacologic management part 1: better-studied neuropathic pain diseases. Pain Med 2004; 5: 28-47.
Ballantyne JC, Mao J. Opioid therapy for chronic pain. New Engl J Med 2003; 349: 1943-53.
Berger A, Dukes EM, Oster G: Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain 2004; 5: 143-149.
Breivik H. Opioids in chronic non-cancer pain, indications and controversies. European Journal of Pain 2005; 9: 127-130.
Buritova J, Besson JM: Peripheral and/or central effects of racemic-, S(+)- and R(-)-flurbiprofen on inflammatory nociceptive processes: A c-Fos protein study in the rat spinal cord. Br J Pharmacol 1998; 125 :87–101.
Can C. Opioid analjezikler Türkiye Klinkleri Dahili T›p Bilimleri Farmakoloji 2005; 1: 15-23.
Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, Simmons DL. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci 2002; 99: 13926-31.
Dani M, Guindon J, Lambert C, Beaulieu P. The local antinoci- ceptive effects of paracetamol in neuropathic pain are mediated by cannabinoid receptors. Eur J Pharmacol 2007; 573: 214–215.
Dobecki DA, Schocket SM, Wallace MS. Update on pharmacotherapy guidelines for the treatment for neuropathic pain. Curr Pain Headache Rep 2006; 10: 185-90.
Duhmke RM, CornBlath DD, Hollingshead JR. Tramadol for neuropathic pain Cochrane Database Syst Rev 2004; 2:CD 003726
Dworkin RH, Backonja M, Rowbotham MC, Allen RR, Argoff CR, Bennett GJ, Bushnell MC, Farrar JT, Galer BS, Haythornthwaite JA, Hewitt DJ, Loeser JD, Max MB, Saltarelli M, Schmader KE, Stein C, Thompson D, Turk DC, Wallace MS, Watkins LR, Weinstein SM. Advances in neuropathic pain. Diagnosis, mechanisms, and treatment recommendations. Arch Neurol 2003; 60: 1524–1534.
Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, Kalso EA, Loeser JD, Miaskowski C, Nurmikko TJ, Portenoy RK, Rice AS, Stacey BR, Treede RD, Turk DC, Wallace MS. Pharmacological management of neuropathic pain: Evidence-based recommen dations Pain 2007; 1323: 237-251.
Eisenberg E, Mc Nicol ED, Carr DB. Efficacy of mu-opioid agonists in the treatment of evoked neuropathic pain. Systematic review of randomized controlled trials European Journal of Pain 2006b; 10: 667-676.
Eisenberg E, Mc Nicol ED, Carr DB. Opioids neuropathic pain. Cochrane Database Syst Rev. 2006a; 3: CD 006146
Eisenberg E, McNicol ED, Carr DB. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin. Systematic review and meta-analy sis of randomized controlled trials. JAMA 2005; 293: 3043-3052.
Ferreira SH, Lorenzetti BB: Intrathecal administration of prostaglandin E2 causes sensitization of the primary afferent neuron via the spinal release of glutamate. Inflamm Res 1996; 45: 499–502.
Ferreira SH, Moncada S, Vane JR: Prostaglandins and the mechanism of analgesia produced by aspirin-like drugs. Br J Pharmacol 1973; 49: 86–97.
Finnerup NB, Otto M, McQuay HJ, jensen TS, Sindrup SH. Algoritm for neuropathic pain treatment. An evidence based proposal. Pain 2005; 118: 289-305
Foley KM. Opioids and chronic neuropathic pain N Engl J Med 2003; 348: 1279-81.
Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic non-cancer pain. A meta-analysis of effective ness and side effects CMAJ 2006; 174: 1589-1594.
Gillis JC, Brogden RN. Ketorolac_a reappraisal of its pharmaco dynamic and pharmacologic properties and therapeutic use in pain management. Drugs 1997; 53: 139-188.
Gilron I, Bailey J, Weaver DF, Houlden RL: Patients' attitudes and prior treatments in neuropathic pain: a pilot study. Pain Res Manag 2002; 7: 199-203.
Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, Gabapentin or their combination for neuropathic pain. N Engl J Med 2005; 352: 1324-1334.
Gilron I, Watson CP, Cahill CM, Moulin DE. Neuropathic pain: a practical guide for the clinician CMAJ 2006; 175: 265-75.
Gimbel JS, Richard P, Portenoy RK. Controlled release oxycodone for pain relief in diabetic neuropathy: a randomized controlled trial. Neurology 2003; 60: 927-934.
Gore M, Dukes E, Rowbotham DJ. Clinical characteristics and pain management among patients with painful periph eral neuropathic disorders in general practice settings.Eur J Pain 2007; 11: 652–664.
Gulcu N, Karaaslan K, Ozturan KE, Kocaoglu H. Intravenous paracetamol for pain relief in a patient with neuropathic pain. Acta Anaesthesiol Scand 2007; 51: 956-7.
Hall GC, Carroll D, Parry D, McQuay HJ. Epidemiology and treatment of neuropathic pain: the UK primary care perspective. Pain 2006; 122: 156–162.
Hans G, Masquelier E and Cock PD. The diagnosis and management of neuropathic pain in daily practice in Belgium: an observational study. BMC Public Health 2007; 7: 170.
Hurley RW, Chatterjea D, Rose Feng M, Taylor CP, Hammond DL. Gabapentin and Pregabalin Can Interact Synergistically with Naproxen to Produce Antihyperalgesia. Anesthesiology 2002; 97: 1263–73.
Huse E, Lorbig W, Birbaumer N. The effect opioids on phantom limb pain and cortical reorganization pain 2001; 90: 47-55.
Ilse WK. Neuropathic pare: Mechanisms, diagnosis and treatment. Can J Continuing Med Education 2002; 14: 99-108.
Jensen PG, Larson JR. Management of painful diabetic neuropathy Drugs Aging 2001; 18: 737-749.
Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: Systematic review of efficacy and safety. Pain 2004; 112: 372-80.
Katafuchi T, Duan S, Take S, Yoshimura M. Modulation of glutamate-induced outward current by prostaglandin E (2) in rat dissociated preoptic neurons. Brain Res 2005; 1037: 180-186.
Kausar F, Davis MP. Ketorolac in Neuropathic Pain. J Pain Symptom Manage 2006; 32: 202-204.
Keskinbora K Opioid analjezikler In: Ağrı Erdine Serdar (Ed) Nobel Tıp Kitapları, İstanbul, 2007; 581-604.
Kosinski MR, Schein JR, Vallow SM. An observational study of health-releated quality of life and pain outcomes in chronic low back pain patients treated with fentanyl transdermal system Curr Med Res Opin 2005; 21:849-862.
Ma W, Eisenach JC. Morphological and pharmacological evidence for the role of peripheral prostaglandins in the pathogenesis of neuropathic pain. Eur J Neurosci 2002;15: 1037-1047.
MacPherson RD. The pharmacological basis of contemporary pain management. Pharmacol Ther 2000; 88: 163-185. McQuay HJ. Opioid use in chronic pain. Acta Anaesthesiol Scand 1997; 41: 175-93.
Mercadante S, Fulfaro F, Casuccio A. A randomized controlled study on the use of antiinflammatory drugs in patients with cancer pain on morphine therapy: effects on dose-escalation and a pharmacoeconomic analysis. Eur J Cancer 2002; 38: 1358-1363.
Merskey H: Logic, truth and language in concepts of pain. Qual Life Res 1994; 3: 69-76.
Michelis JJ. Platelet-mediated microvascular inflammation and thrombosis in thrombocythemia vera: A distinct aspirin-responsive arterial thrombophilia, which transforms into a bleeding diathesis at increasing platelet counts. Pathol Bid 2003; 51: 167-175.
Morley JS, Bridson J, Nash TP, Miles JB, White S, Makin MK. Low-dose methadone has analgesic effect in neuropathic pain.adouble-blind randomized controlled cross-over trial. Palliat Med 2003; 17: 576-587.
Moulin DE, Clark AJ, Gilron I, Ware MA, Watson CP, Sessle BJ, Coderre T, Morley-Forster PK, Stinson J, Boulanger A, Peng P, Finley GA, Taenzer P, Squire P, Dion D, Cholkan A, Gilani A, Gordon A, Henry J, Jovey R, Lynch M, Mailis-Gagnon A, Panju A, Rollman GB, Velly A; Canadian Pain Society. Pharmagological management of chronic neuropathic pain consensus statement and guidelines from the Canadian Pain Society. Pain Res Manage 2007; 12: 13-21.
Myers KG, Trotman IF. Use of ketorolac by continuous subcutaneous infusion for the control of cancer-related pain. Postgrad Med J 1994; 70: 359-362.
Nalamachu S, Gammaitoni AR, Gould EM. A Comparison of the Lidocaine Patch 5% vs Naproxen 500 mg Twice Daily for the Relief of Pain Associated With Carpal Tunnel Syndrome: A 6-Week, Randomized, Parallel-Group Study. Med Gen Med 2006; 8: 33.
Namaka M, Gramlich CR, Ruhlen D, et al. A treatment algorithm for neuropathic pain. Clin Ther 2004; 26: 951-979.
Otis J, Rothman M. A phase III study to assess the clinical utility of low-dose fentanyl transdermal system in patients with chronic non-malignant pain. Curr Medical Research and Opinion 2006; 22: 1493-1501.
Palangio M, Damask MJ, Morris E, Doyle RT Jr, Jiang JG, Landau CJ, de Padova A. Combination hydrocodone and ibuprofen versus combination codeine and acetammophen for the treatment of chronic pain. Clin Ther 2000; 22: 879-892.
Peripheral vascular disorders. In: Beers MH, Berkow R, eds. Merck Manual. 17th ed. Whitehouse Station, NJ: Merck Research Laboratories; 1999: 1786-1791.
Raffa RB. Pharmacology of oral combination analgesics: Rational therapy for pain J Clin Pharm Ther 2001; 26: 257-264.
Raja SN, Haythornthwaite JA, Pappagallo M, Clark MR, Travison TG, Sabeen S, Royall RM, Max MB. Opioids versus antidepressants in postherpetic neuralgia: a randomized placebo controlled trial Neurology 2002; 59: 1015-1021.
Rice ASC, Hill RG. New treatment for neuropathic pain. Annu Rev Med 2006; 7: 535–551.
Ripamonti C, Ticozzi C, Zecca E, Rodriguez CH, De Conno F. Continuous subcutaneous infusion of ketorolac in cancer neuropathic pain unresponsive to opioid and adjuvant drugs. A case report. Tumori 1996; 82: 413-415.
Rowbothorm MC, Twillig L, Davies PS, Reisner L, Taylor, K, Mohr D. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med 2003; 348: 1223-1232.
Schofferman J, Mostoufi SA. Opioid Analgesics In. Interventional Spine analgorithmic approach. Slipman C, Derby R, Simeone FA, Mayer TG (Eds) 2008; 161-172.
Stacey BR. Management of peripheral neuropathic pain. Am J Phys Med Rehabil 2005; 84: 4-16.
Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain randomized trial in postherpetic neuralgia Neurology 1998; 50: 1937-1944.
Watson CP, Moulin D. Watt-Watson J, Gordon A, Eisenhoffer J. Controlled –release oxycodone relieves neuropathic pain.a randomized controlled trial in painful diabetic neuropathy. Pain 2003; 105: 71-78.
Woolf CJ, Max MB. Mechanism-based pain diagnosis: issues for analgesic drug development. Anesthesiology 2001; 95: 241–249.